IDEAS home Printed from https://ideas.repec.org/a/spr/aphecp/v10y2012i3p175-188.html
   My bibliography  Save this article

Cost effectiveness of prostacyclins in pulmonary arterial hypertension

Author

Listed:
  • Antonio Roman
  • Joan Barberà
  • Pilar Escribano
  • Maria Sala
  • Laia Febrer
  • Itziar Oyagüez
  • Eliazar Sabater
  • Miguel Casado

Abstract

Initiating prostacyclin treatment with iloprost in patients with PAH, functional class III of the NYHA, is the less costly alternative for the NHS in Spain, with a good efficacy profile when compared with the other alternatives. Copyright Springer International Publishing AG 2012

Suggested Citation

  • Antonio Roman & Joan Barberà & Pilar Escribano & Maria Sala & Laia Febrer & Itziar Oyagüez & Eliazar Sabater & Miguel Casado, 2012. "Cost effectiveness of prostacyclins in pulmonary arterial hypertension," Applied Health Economics and Health Policy, Springer, vol. 10(3), pages 175-188, May.
    • Handle: RePEc:spr:aphecp:v:10:y:2012:i:3:p:175-188
    DOI: 10.2165/11630780-000000000-00000
    as

    Download full text from publisher

    File URL: http://hdl.handle.net/10.2165/11630780-000000000-00000
    Download Restriction: Access to full text is restricted to subscribers.
    File URL: https://libkey.io/10.2165/11630780-000000000-00000?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. George Dranitsaris & Sanjay Mehta, 2009. "Oral therapies for the treatment of pulmonary arterial hypertension," Applied Health Economics and Health Policy, Springer, vol. 7(1), pages 43-59, March.
    2. John Wlodarczyk & Leslie Cleland & Anne Keogh & Keith McNeil & Kate Perl & Robert Weintraub & Trevor Williams, 2006. "Public Funding of Bosentan for the Treatment of Pulmonary Artery Hypertension in Australia," PharmacoEconomics, Springer, vol. 24(9), pages 903-915, September.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Kathryn Coyle & Doug Coyle & Julie Blouin & Karen Lee & Mohammed F. Jabr & Khai Tran & Lisa Mielniczuk & John Swiston & Mike Innes, 2016. "Cost Effectiveness of First-Line Oral Therapies for Pulmonary Arterial Hypertension: A Modelling Study," PharmacoEconomics, Springer, vol. 34(5), pages 509-520, May.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Antonio Roman & Joan A. Barberà & Pilar Escribano & Maria L. Sala & Laia Febrer & Itziar Oyagüez & Eliazar Sabater & Miguel Á. Casado, 2012. "Cost effectiveness of prostacyclins in pulmonary arterial hypertension," Applied Health Economics and Health Policy, Springer, vol. 10(3), pages 175-188, May.
    2. Simon Walker & Mark Sculpher & Karl Claxton & Steve Palmer, 2012. "Coverage with evidence development, only in research, risk sharing or patient access scheme? A framework for coverage decisions," Working Papers 077cherp, Centre for Health Economics, University of York.
    3. George Dranitsaris & Sanjay Mehta, 2009. "Oral therapies for the treatment of pulmonary arterial hypertension," Applied Health Economics and Health Policy, Springer, vol. 7(1), pages 43-59, March.
    4. Carlson, Josh J. & Sullivan, Sean D. & Garrison, Louis P. & Neumann, Peter J. & Veenstra, David L., 2010. "Linking payment to health outcomes: A taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers," Health Policy, Elsevier, vol. 96(3), pages 179-190, August.
    5. Lou Garrison;Ruth Puig-Peiro;Adrian Towse, 2012. "The Use of Pay-for-Performance for Drugs: Can It Improve Incentives for Innovation?," Occasional Paper 000167, Office of Health Economics.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:aphecp:v:10:y:2012:i:3:p:175-188. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.